suck pdf from google scholar
unlimited free pdf from europmc18311159    free
PDF from PMC    free
html from PMC    free
PDF vom PMID18311159 :   free
PDF vom PMID18311159
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text


  • DeepDyve
  • Pubget Overpricing


  • lll
  • Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells
  • Sitkovsky M; Lukashev D; Deaglio S; Dwyer K; Robson SC; Ohta A
  • Br J Pharmacol 2008[Mar]; 153 Suppl 1 (): S457-64
  • The intensity and duration of host responses are determined by protective mechanisms that control tissue injury by dampening down inflammation. Adenosine generation and consequent effects, mediated via A2A adenosine receptors (A2AR) on effector cells, play a critical role in the pathophysiological modulation of these responses in vivo. Adenosine is both released by hypoxic cells/tissues and is also generated from extracellular nucleotides by ecto-enzymes e.g. CD39 (ENTPD1) and CD73 that are expressed by the vasculature and immune cells, in particular by T regulatory cell. In general, these adenosinergic mechanisms minimize the extent of collateral damage to host tissues during the course of inflammatory reactions. However, induction of suppressive pathways might also cause escape of pathogens and permit dissemination. In addition, adenosinergic responses may inhibit immune responses while enhancing vascular angiogenic responses to malignant cells that promote tumor growth. Novel drugs that block A2AR-adenosinergic effects and/or adenosine generation have the potential to boost pathogen destruction and to selectively destroy malignant tissues. In the latter instance, future treatment modalities might include novel 'anti-adenosinergic' approaches that augment immune clearance of malignant cells and block permissive angiogenesis. This review addresses several possible pharmacological modalities to block adenosinergic pathways and speculates on their future application together with impacts on human disease.
  • |*Adenosine A2 Receptor Antagonists[MESH]
  • |Adenosine/antagonists & inhibitors/metabolism/*physiology[MESH]
  • |Animals[MESH]
  • |Extracellular Space/metabolism[MESH]
  • |Humans[MESH]
  • |Immunotherapy[MESH]
  • |Inflammation/immunology/pathology[MESH]
  • |Receptors, G-Protein-Coupled/drug effects[MESH]
  • |T-Lymphocytes, Regulatory/*drug effects/immunology[MESH]





  • *{{pmid18311159}}
    *<b>[http://www.kidney.de/mlpefetch.php?search=18311159 Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells ]</b> Br J Pharmacol 2008; 153 Suppl 1() ; S457-64 Sitkovsky M; Lukashev D; Deaglio S; Dwyer K; Robson SC; Ohta A

        *18311159*

    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren

    Br J Pharmacol

    S457 .153 Suppl 1 2008